x
|
QUARTERLY
REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
|
o
|
TRANSITION
REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Delaware
|
20-8133057
|
|
(State or other jurisdiction
of
incorporation or
organization)
|
(I.R.S. Employer
Identification
No.)
|
Large
accelerated filer o
|
Accelerated
filer o
|
|
Non-accelerated filer o (Do not check if a smaller reporting company) |
Smaller
reporting company x
|
Page
Number
|
||
PART
I
|
1
|
|
Item
1. Financial Statements
|
1
|
|
Item
2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
|
33
|
|
Item
3. Quantitative and Qualitative Disclosures About Market
Risk
|
38
|
|
Item
4. Controls and Procedures
|
38
|
|
PART
II
|
39
|
|
Item
1. Legal Proceedings
|
39
|
|
Item
1A. Risk Factors
|
40
|
|
Item
5. Other Information
|
40
|
|
Item
6. Exhibits
|
40
|
Page
|
|
Consolidated
Balance Sheets
|
3
|
|
|
Consolidated
Statements of Operations
|
4
|
|
|
Statements
of Changes in Stockholders' Equity (Deficiency)
|
5 -
9
|
|
|
Consolidated
Statements of Cash Flows
|
10 -
11
|
|
|
Notes
to Consolidated Financial Statements
|
12
- 32
|
September
30,
|
December
31,
|
|||||||
2009
|
2008
|
|||||||
Unaudited
|
Audited
|
|||||||
ASSETS
|
||||||||
CURRENT
ASSETS:
|
||||||||
Cash
and cash equivalents
|
$ | 2 | $ | 2 | ||||
Restricted
cash
|
- | 36 | ||||||
Accounts
receivable and prepaid expenses
|
93 | 21 | ||||||
Total
current assets
|
95 | 59 | ||||||
LONG-TERM
INVESTMENTS:
|
||||||||
Prepaid
expenses
|
7 | 11 | ||||||
Severance
pay fund
|
79 | 62 | ||||||
Total
long-term investments
|
86 | 73 | ||||||
PROPERTY
AND EQUIPMENT, NET
|
624 | 743 | ||||||
Total
assets
|
$ | 805 | $ | 875 | ||||
LIABILITIES
AND STOCKHOLDERS' DEFICIENCY
|
||||||||
CURRENT
LIABILITIES:
|
||||||||
Short
term Credit from bank
|
$ | 78 | $ | 72 | ||||
Trade
payables
|
777 | 744 | ||||||
Other
accounts payable and accrued expenses
|
2,231 | 1,672 | ||||||
Short-term
convertible loans
|
186 | 172 | ||||||
Short-term
loans
|
- | 199 | ||||||
Total
current liabilities
|
3,272 | 2,859 | ||||||
ACCRUED
SEVERANCE PAY
|
101 | 92 | ||||||
Total
liabilities
|
3,373 | 2,951 | ||||||
COMMITMENTS
AND CONTINGENCIES
|
||||||||
STOCKHOLDERS'
DEFICIENCY:
|
||||||||
Stock
capital: (Note 7)
|
||||||||
Common
stock of $0.00005 par value - Authorized: 800,000,000 shares as of
September 30, 2009 and December 31, 2008; Issued and outstanding:
60,505,702 and 55,241,418 shares as of September 30, 2009
and December 31, 2008, respectively.
|
3 | 3 | ||||||
Additional
paid-in-capital
|
35,067 | 33,881 | ||||||
Deficit
accumulated during the development stage
|
(37,638 | ) | (35,960 | ) | ||||
Total
stockholders' deficiency
|
(2,568 | ) | (2,076 | ) | ||||
Total
liabilities and stockholders' deficiency
|
$ | 805 | $ | 875 | ||||
Three
months ended
September
30,
|
Nine
months ended
September
30,
|
Period
from September 22, 2000 (inception date) through
September
30,
|
||||||||||||||||||
2009
|
2008
|
2009
|
2008
|
2009
|
||||||||||||||||
Unaudited
|
Unaudited
|
Unaudited
|
||||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||
Research
and development, net
|
$ | 275 | $ | 292 | $ | 774 | $ | 1,165 | $ | 22,278 | ||||||||||
General
and administrative
|
318 | 405 | 883 | 1,428 | 12,572 | |||||||||||||||
Total
operating costs and expenses
|
593 | 697 | 1,657 | 2,593 | 34,850 | |||||||||||||||
Financial
expenses (income), net
|
28 | 31 | 21 | 253 | 2,571 | |||||||||||||||
621 | 728 | 1,678 | 2,846 | 37,421 | ||||||||||||||||
Taxes
on income
|
- | - | - | - | 53 | |||||||||||||||
Loss
from continuing operations
|
621 | 728 | 1,678 | 2,846 | 37,474 | |||||||||||||||
Net
loss from discontinued operations
|
- | - | - | - | 164 | |||||||||||||||
Net
loss
|
$ | 621 | $ | 728 | $ | 1,678 | $ | 2,846 | $ | 37,638 | ||||||||||
Basic
and diluted net loss per share from continuing operations
|
$ | 0.01 | $ | 0.01 | $ | 0.03 | $ | 0.06 | ||||||||||||
Weighted
average number of shares outstanding used in computing basic and diluted
net loss per share
|
60,390,796 | 51,354,951 | 58,327,655 | 46,958,440 | ||||||||||||||||
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of September 22, 2000 (date of inception)
|
- | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||||||||
|
||||||||||||||||||||||||
Stock
issued on September 22, 2000 for cash at $0.00188 per
share
|
8,500,000 | 1 | 16 | - | - | 17 | ||||||||||||||||||
Stock
issued on March 31, 2001 for cash at $0.0375 per share
|
1,600,000 | * - | 60 | - | - | 60 | ||||||||||||||||||
Contribution
of capital
|
- | - | 8 | - | - | 8 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (17 | ) | (17 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of March 31, 2001
|
10,100,000 | 1 | 84 | - | (17 | ) | 68 | |||||||||||||||||
|
||||||||||||||||||||||||
Contribution
of capital
|
- | - | 11 | - | - | 11 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (26 | ) | (26 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of March 31, 2002
|
10,100,000 | 1 | 95 | - | (43 | ) | 53 | |||||||||||||||||
|
||||||||||||||||||||||||
Contribution
of capital
|
- | - | 15 | - | - | 15 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (47 | ) | (47 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of March 31, 2003
|
10,100,000 | 1 | 110 | - | (90 | ) | 21 | |||||||||||||||||
|
||||||||||||||||||||||||
2-for-1
stock split
|
10,100,000 | * - | - | - | - | - | ||||||||||||||||||
Stock
issued on August 31, 2003 to purchase mineral option at $0.065 per
share
|
100,000 | * - | 6 | - | - | 6 | ||||||||||||||||||
Cancellation
of shares granted to Company's President
|
(10,062,000 | ) | * - | * - | - | - | - | |||||||||||||||||
Contribution
of capital
|
- | * - | 15 | - | - | 15 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (73 | ) | (73 | ) | ||||||||||||||||
Balance
as of March 31, 2004
|
10,238,000 | $ | 1 | $ | 131 | $ | - | $ | (163 | ) | $ | (31 | ) |
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of March 31, 2004
|
10,238,000 | $ | 1 | $ | 131 | $ | - | $ | (163 | ) | $ | (31 | ) | |||||||||||
Stock
issued on June 24, 2004 for private placement at $0.01 per share, net of
$25,000 issuance expenses
|
8,510,000 | * - | 60 | - | - | 60 | ||||||||||||||||||
Contribution
capital
|
- | - | 7 | - | - | 7 | ||||||||||||||||||
Stock
issued in 2004 for private placement at $0.75 per unit
|
1,894,808 | * - | 1,418 | - | - | 1,418 | ||||||||||||||||||
Cancellation
of shares granted to service providers
|
(1,800,000 | ) | * - | - | - | - | ||||||||||||||||||
Deferred
stock-based compensation related to options granted to
employees
|
- | - | 5,979 | (5,979 | ) | - | - | |||||||||||||||||
Amortization
of deferred stock-based compensation related to shares and options granted
to employees
|
- | - | - | 584 | - | 584 | ||||||||||||||||||
Compensation
related to shares and options granted to service providers
|
2,025,000 | * - | 17,506 | - | - | 17,506 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (18,840 | ) | (18,840 | ) | ||||||||||||||||
Balance
as of March 31, 2005
|
20,867,808 | $ | 1 | $ | 25,101 | $ | (5,395 | ) | $ | (19,003 | ) | $ | 704 |
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of March 31, 2005
|
20,867,808 | $ | 1 | $ | 25,101 | $ | (5,395 | ) | $ | (19,003 | ) | $ | 704 | |||||||||||
|
||||||||||||||||||||||||
Stock
issued on May 12, 2005 for private placement at $0.8 per
share
|
186,875 | * - | 149 | - | - | 149 | ||||||||||||||||||
Stock
issued on July 27, 2005 for private placement at $0.6 per
share
|
165,000 | * - | 99 | - | - | 99 | ||||||||||||||||||
Stock
issued on September 30, 2005 for private placement at $0.8 per
share
|
312,500 | * - | 225 | - | - | 225 | ||||||||||||||||||
Stock
issued on December 7, 2005 for private placement at $0.8 per
share
|
187,500 | * - | 135 | - | - | 135 | ||||||||||||||||||
Forfeiture
of options granted to employees
|
- | - | (3,363 | ) | 3,363 | - | - | |||||||||||||||||
Deferred
stock-based compensation related to shares and options granted to
directors and employees
|
200,000 | * - | 486 | (486 | ) | - | - | |||||||||||||||||
Amortization
of deferred stock-based compensation related to options and shares granted
to employees and directors
|
- | - | 51 | 1,123 | - | 1,174 | ||||||||||||||||||
Stock-based
compensation related to options and shares granted to service
providers
|
934,904 | * - | 662 | - | - | 662 | ||||||||||||||||||
Reclassification
due to application of EITF
00-19 (ASC 815-40-25)
|
- | - | (7,906 | ) | (7,906 | ) | ||||||||||||||||||
Beneficial
conversion feature related to a convertible bridge loan
|
- | - | 164 | - | - | 164 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (3,317 | ) | (3,317 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of March 31, 2006
|
22,854,587 | $ | 1 | $ | 15,803 | $ | (1,395 | ) | $ | (22,320 | ) | $ | (7,911 | ) | ||||||||||
|
||||||||||||||||||||||||
Elimination
of deferred stock compensation due to implementation of SFAS 123(R) (ASC
718-10)
|
- | - | (1,395 | ) | 1,395 | - | - | |||||||||||||||||
Stock-based
compensation related to shares and options granted to directors and
employees
|
200,000 | * - | 1,168 | - | - | 1,168 | ||||||||||||||||||
Reclassification
due to application of EITF
00-19 (ASC 815-40-25)
|
- | - | 7,191 | - | - | 7,191 | ||||||||||||||||||
Stock-based
compensation related to options and shares granted to service
providers
|
1,147,225 | - | 453 | - | - | 453 | ||||||||||||||||||
Warrants
issued to convertible note holder
|
- | - | 11 | - | - | 11 | ||||||||||||||||||
Warrants
issued to loan holder
|
- | - | 110 | - | - | 110 | ||||||||||||||||||
Beneficial
conversion feature related to convertible bridge loans
|
- | - | 1,086 | - | - | 1,086 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (3,924 | ) | (3,924 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of December 31, 2006
|
24,201,812 | $ | 1 | $ | 24,427 | $ | - | $ | (26,244 | ) | $ | (1,816 | ) |
*
Represents an amount less than $1.
|
Deficit
accumulated
|
Total
|
|||||||||||||||||||||||
Additional
|
Deferred
|
during
the
|
stockholders'
|
|||||||||||||||||||||
Common
stock
|
paid-in
|
stock-based
|
development
|
equity
|
||||||||||||||||||||
Number
|
Amount
|
Capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of December 31, 2006
|
24,201,812 | $ | 1 | $ | 24,427 | $ | - | $ | (26,244 | ) | $ | (1,816 | ) | |||||||||||
|
||||||||||||||||||||||||
Stock-based
compensation related to options and shares granted to service
providers
|
544,095 | 1,446 | - | - | 1,446 | |||||||||||||||||||
Warrants
issued to convertible note holder
|
- | - | 109 | - | - | 109 | ||||||||||||||||||
Stock-based
compensation related to shares and options granted to directors and
employees
|
200,000 | * - | 1,232 | - | - | 1,232 | ||||||||||||||||||
Beneficial
conversion feature related to convertible loans
|
- | - | 407 | - | - | 407 | ||||||||||||||||||
Conversion
of convertible loans
|
725,881 | * - | 224 | - | - | 224 | ||||||||||||||||||
Exercise
of warrants
|
3,832,621 | * - | 214 | - | - | 214 | ||||||||||||||||||
Stock
issued for private placement at $0.1818 per unit, net of finder's
fee
|
11,500,000 | 1 | 1,999 | - | - | 2,000 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (6,244 | ) | (6,244 | ) | ||||||||||||||||
|
||||||||||||||||||||||||
Balance
as of December 31, 2007
|
41,004,409 | $ | 2 | $ | 30,058 | $ | - | $ | (32,488 | ) | $ | (2,428 | ) | |||||||||||
|
||||||||||||||||||||||||
Stock-based
compensation related to options and stock granted to service
providers
|
90,000 | - | 33 | - | - | 33 | ||||||||||||||||||
Stock-based
compensation related to stock and options granted to directors and
employees
|
- | 731 | - | - | 731 | |||||||||||||||||||
Conversion
of convertible loans
|
3,644,610 | * - | 1,276 | - | - | 1,276 | ||||||||||||||||||
Exercise
of warrants
|
1,860,000 | * - | - | - | - | - | ||||||||||||||||||
Exercise
of options
|
17,399 | * - | 3 | - | - | 3 | ||||||||||||||||||
Stock
issued for private placement at $0.1818 per unit, net of finder's
fee
|
8,625,000 | 1 | 1,499 | - | - | 1,500 | ||||||||||||||||||
Subscription
of shares for private placement at $0.1818 per
unit
|
- | - | 281 | - | - | 281 | ||||||||||||||||||
Net
loss
|
- | - | - | - | (3,472 | ) | (3,472 | ) | ||||||||||||||||
Balance
as of December 31, 2008
|
55,241,418 | $ | 3 | $ | 33,881 | $ | - | $ | (35,960 | ) | $ | (2,076 | ) | |||||||||||
|
Common
stock
|
Additional
paid-in
|
Deferred
stock-based
|
Deficit
accumulated
during
the
development
|
Total
stockholders'
|
||||||||||||||||||||
Number
|
Amount
|
capital
|
compensation
|
stage
|
(deficiency)
|
|||||||||||||||||||
Balance
as of December 31, 2008
|
55,241,418 | $ | 3 | $ | 33,881 | $ | - | $ | (35,960 | ) | $ | (2,076 | ) | |||||||||||
|
||||||||||||||||||||||||
Conversion
of convertible loans
|
2,500,000 | * - | 200 | - | - | 200 | ||||||||||||||||||
Stock-based
compensation related to options and stock granted to service
providers
|
2,764,284 | * - | 270 | - | - | 270 | ||||||||||||||||||
Stock-based
compensation related to stock and options granted to directors and
employees
|
- | - | 293 | - | - | 293 | ||||||||||||||||||
Subscription
of shares for private placement
|
423 | 423 | ||||||||||||||||||||||
Net
loss
|
- | - | - | - | (1,678 | ) | (1,678 | ) | ||||||||||||||||
Balance
as of September 30, 2009
|
60,505,702 | $ | 3 | $ | 35,067 | $ | - | $ | (37,638 | ) | $ | (2,568 | ) |
Nine
months
ended
September 30,
|
Period
from September 22, 2000 (inception date) through
September
30,
|
|||||||||||
2009
|
2008
|
2009
|
||||||||||
Unaudited
|
Unaudited
|
|||||||||||
Cash
flows from operating activities:
|
||||||||||||
Net
loss
|
$ | (1,678 | ) | $ | (2,846 | ) | $ | (37,638 | ) | |||
Less
- loss for the period from discontinued operations
|
- | - | 164 | |||||||||
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
||||||||||||
Depreciation
and amortization of deferred charges
|
120 | 113 | 638 | |||||||||
Erosion
of restricted cash
|
35 | (5 | ) | 29 | ||||||||
Accrued
severance pay, net
|
(8 | ) | 20 | 22 | ||||||||
Accrued
interest on loans
|
14 | 108 | 444 | |||||||||
Amortization
of discount on short-term loans
|
- | 42 | 1,865 | |||||||||
Change
in fair value of options and warrants
|
- | - | (795 | ) | ||||||||
Expenses
related to stocks and options granted to service providers
|
270 | 97 | 20,436 | |||||||||
Amortization
of deferred stock-based compensation related to options granted to
employees and directors
|
293 | 478 | 5,182 | |||||||||
Decrease
(increase) in accounts receivable and prepaid expenses
|
(71 | ) | 49 | (93 | ) | |||||||
Increase
(decrease) in trade payables
|
33 | (101 | ) | 777 | ||||||||
Increase
in other accounts payable and accrued expenses
|
559 | 456 | 2,225 | |||||||||
Net
cash used in continuing operating activities
|
(433 | ) | ( 1,589 | ) | (6,744 | ) | ||||||
Net
cash used in discontinued operating activities
|
- | - | (23 | ) | ||||||||
Total
net cash used in operating activities
|
(433 | ) | (1,589 | ) | (6,767 | ) | ||||||
|
||||||||||||
Cash flows from
investing activities:
|
||||||||||||
Purchase
of property and equipment
|
- | (154 | ) | (1,080 | ) | |||||||
Restricted
cash
|
- | - | (29 | ) | ||||||||
Investment
in lease deposit
|
4 | (4 | ) | (7 | ) | |||||||
Net
cash used in continuing investing activities
|
4 | (158 | ) | (1,116 | ) | |||||||
Net
cash used in discontinued investing activities
|
- | - | (16 | ) | ||||||||
Total
net cash provided by (used in) investing activities
|
$ | 4 | $ | (158 | ) | $ | (1,132 | ) | ||||
Nine
months
ended
September 30,
|
Period
from September 22, 2000 (inception date) through
September
30,
|
|||||||||||
2009
|
2008
|
2009
|
||||||||||
Unaudited
|
Unaudited
|
|||||||||||
Cash flows from
financing activities:
|
||||||||||||
Proceeds
from issuance of common stock and warrants
|
$ | 423 | $ | 1,634 | $ | 6,292 | ||||||
Proceeds
from loans, notes and issuance of warrants net
|
- | - | 2,061 | |||||||||
Change
in credit from bank
|
6 | 95 | 78 | |||||||||
Repayment
of loans
|
- | (50 | ) | (601 | ) | |||||||
Proceeds
from exercise of warrants and options
|
- | 3 | 28 | |||||||||
Net
cash provided by continuing financing activities
|
429 | 1,682 | 7,858 | |||||||||
Net
cash provided by discontinued financing activities
|
- | - | 43 | |||||||||
Total
net cash provided by financing activities
|
429 | 1,682 | 7,901 | |||||||||
|
||||||||||||
Increase
(decrease) in cash and cash equivalents
|
- | (65 | ) | 2 | ||||||||
Cash
and cash equivalents at the beginning of the period
|
2 | 86 | - | |||||||||
Cash
and cash equivalents at end of the period
|
$ | 2 | $ | 21 | $ | 2 | ||||||
A.
|
On
July 8, 2004, the Company entered into a licensing agreement with Ramot of
Tel Aviv University Ltd. ("Ramot"), an Israeli corporation, to acquire
certain stem cell technology (see Note 3). Subsequent to this agreement,
the Company decided to focus on the development of novel cell therapies
for neurodegenerative diseases, particularly Parkinson's and ALS disease,
based on the acquired technology and research to be conducted and funded
by the Company.
|
B.
|
On
October 25, 2004, the Company formed a wholly-owned subsidiary in Israel,
Brainstorm Cell Therapeutics Ltd.
("BCT").
|
C.
|
On
November 22, 2004, the Company changed its name from Golden Hand Resources
Inc. to Brainstorm Cell Therapeutics Inc. to better reflect its new line
of business in the development of novel cell therapies for
neurodegenerative diseases. BCT owns all operational property and
equipment.
|
D.
|
In
December 2006, the Company changed its state of incorporation from
Washington to Delaware.
|
E.
|
On
September 17, 2006, the Company changed its fiscal year-end from March 31
to December 31.
|
F.
|
Since
its inception, the Company has devoted substantially most of its efforts
to research and development, recruiting management and technical staff,
acquiring assets and raising capital. In addition, the Company has not
generated revenues. Accordingly, the Company is considered to be in the
development stage, as defined in Statement of Financial Accounting
Standards No. 7 (ASC 915-10), "Accounting and reporting by development
Stage Enterprises" ("SFAS
No. 7").
|
A.
|
On
July 26, 2007, the Company entered into a Second Amended and Restated
Research and License Agreement with Ramot. On August 1, 2007, the Company
obtained a waiver and release from Ramot pursuant to which Ramot agreed to
an amended payment schedule regarding the Company's payment obligations
under the Amended Research and License Agreement, dated March 30, 2006,
and waived all claims against the Company resulting from the Company's
previous defaults and non-payment under the original agreement and the
Amended Research and License Agreement. The payments described in the
waiver and release covered all payment obligations that were past due and
not yet due pursuant to the original agreement. The waiver and release
amends and restates the original payment schedule under the original
agreement as follows:
|
Payment
date
|
Amount
|
|||
September
5, 2007
|
100 | |||
November
20, 2007
|
150 | |||
February
20, 2008
|
150 | |||
May
20, 2008
|
150 | |||
August
4, 2008
|
90 |
Payment
date
|
Amount
|
|||
August
4, 2008
|
60 | |||
November
20, 2008
|
150 | |||
February
20, 2009
|
170 |
B.
|
The
Company's total current obligation to Ramot as of September 30, 2009 is in
the amount of $1,057. The amount includes $760 for the extended research
period that the Company is currently negotiating with
Ramot.
|
A.
|
On
July 8, 2004, the Company entered into two consulting agreements with
Prof. Eldad Melamed and Dr. Daniel Offen (together, the "Consultants"),
upon which the Consultants shall provide the Company scientific and
medical consulting services in consideration for a monthly payment of $6
each. In addition, the Company granted each of the Consultants a fully
vested warrant to purchase 1,097,215 shares of Common Stock at an exercise
price of $0.01 per share. The warrants issued pursuant to the agreement
were issued to the Consultants effective as of November 4, 2004. Each of
the warrants is exercisable for a seven-year period beginning on November
4, 2005.
|
B.
|
As
of September 30, 2009, the Company has a total obligation of $334 for
services rendered by the
Consultants.
|
Payment
date
|
Amount
|
|||
May
30, 2008
|
50 | |||
July
31, 2008
|
50 | |||
September
30, 2008
|
50 | |||
December
31, 2008
|
50 | |||
February
28, 2009
|
50 |
A.
|
The
rights of Common Stock are as
follows:
|
B.
|
Issuance
of shares, warrants and
options:
|
1.
|
Private
placements:
|
a)
|
On
June 24, 2004, the Company issued to investors 8,510,000 shares of Common
Stock for total proceeds of $60 (net of $25 issuance
expenses).
|
b)
|
On
February 23, 2005, the Company completed a private placement for sale of
1,894,808 units for total proceeds of $1,418. Each unit consists of one
share of Common Stock and a three-year warrant to purchase one share of
Common Stock at $2.50 per share. This private placement was consummated in
three tranches which closed in October 2004, November 2004 and February
2005.
|
c)
|
On
May 12, 2005, the Company issued to an investor 186,875 shares of Common
Stock for total proceeds of $149 at a price of $0.8 per
share.
|
d)
|
On
July 27, 2005, the Company issued to investors 165,000 shares of Common
Stock for total proceeds of $99 at a price of $0.6 per
share.
|
e)
|
On
August 11, 2005, the Company signed a private placement agreement with
investors for the sale of up to 1,250,000 units at a price of $0.8 per
unit. Each unit consists of one share of Common Stock and one warrant to
purchase one share of Common Stock at $1.00 per share. The warrants are
exercisable for a period of three years from issuance. On September 30,
2005, the Company sold 312,500 units for total net proceeds of $225. On
December 7, 2005, the Company sold 187,500 units for total net proceeds of
$135.
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
1.
|
Private
placements: (Cont.)
|
|
f)
|
On
July 2, 2007, the Company entered into an investment agreement, pursuant
to which the Company agreed to sell up to 27,500,000 shares of Common
Stock, for an aggregate subscription price of up to $5 million and
warrants to purchase up to 30,250,000 shares of Common Stock. Separate
closings of the purchase and sale of the shares and the warrants shall
take place as follows:
|
Purchase
date
|
Purchase
price
|
Number
of subscription shares
|
Number
of warrant shares
|
|||
August
30, 2007
|
$1,250
(includes $250 paid as a convertible loan (Note 8i))
|
6,875,000
|
7,562,500
|
|||
November
15, 2007
|
$750
|
4,125,000
|
4,537,500
|
|||
February
15, 2008
|
$750
|
4,125,000
|
4,537,500
|
|||
May
15, 2008
|
$750
|
4,125,000
|
4,537,500
|
|||
July
30, 2008
|
$750
|
4,125,000
|
4,537,500
|
|||
November
15, 2008
|
$750
|
4,125,000
|
4,537,500
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
1.
|
Private
placements: (Cont.)
|
|
f)
|
Cont.
|
a.
|
The
investor shall invest the remaining amount of the original investment
agreement at price per share of $0.12 in monthly installments of not less
then $50 starting August 1, 2009.
|
b.
|
The
exercise price of the last 10,083,334 warrants will decrease from an
exercise price of $0.36 per share to $0.29 per
share.
|
c.
|
All
warrants will expire on November 5, 2013 instead of November 5,
2011.
|
d.
|
The
price per share of the investment agreement shall decreased from $0.1818
to $0.12, Therefore the Company shall adjust the number of Shares of
Common Stock issuable pursuant the investment agreement retroactively and
shall issue to the investor additional 9,916,667 Shares of Common Stock.
On October 28, 2009, the Shares of Common Stock were
issued.
|
e.
|
The
investor shall have the right to cease payments in the event that the
price per share as of the closing on five consecutive trading days shall
decrease to $0.05.
|
|
2.
|
Share-based
compensation to employees and to
directors:
|
|
a)
|
Options
to employees and directors:
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
|
a)
|
Options
to employees and directors: (Cont.)
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
|
a)
|
Options
to employees and directors: (Cont.)
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
|
a)
|
Options
to employees and directors: (Cont.)
|
Nine
months ended
September
30,
|
Year
ended
December
31,
|
|||||||||||||||
2009
|
2008
|
|||||||||||||||
Amount
of options
|
Weighted
average exercise price
|
Amount
of options
|
Weighted
average exercise price
|
|||||||||||||
$
|
$ | |||||||||||||||
Outstanding
at beginning of period
|
5,433,361 | 0.244 | 5.280.760 | 0.372 | ||||||||||||
Granted
|
1,550,000 | 0.077 | 170,000 | 0.49 | ||||||||||||
Exercised
|
- | - | (17,399 | ) | 0.15 | |||||||||||
Forfeited
|
(120,000 | ) | 0.498 | - | - | |||||||||||
Outstanding
at end of period
|
6,863,361 | 0.20 | 5,433,361 | 0.244 | ||||||||||||
Vested
and expected-to-vest at end of period
|
4,630,375 | 0.24 | 4,324,437 | 0.238 |
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
2.
|
Share-based
compensation to employees and to directors:
(Cont.)
|
|
b)
|
Restricted
shares to directors:
|
|
3.
|
Shares
and warrants to service providers:
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
|
a)
|
Warrants:
|
Issuance
date
|
Number
of
warrants
issued
|
Exercised
|
Forfeited
|
Outstanding
|
Exercise
Price
$
|
Warrants
exercisable
|
Exercisable
through
|
|||||||||||||||||||||
November
2004
|
12,800,845 | 3,141,925 | 40,000 | 9,618,920 | 0.01 | 9,618,920 |
November
2012
|
|||||||||||||||||||||
December
2004
|
1,800,000 | 1,800,000 | - | 0.00005 | -- | - | ||||||||||||||||||||||
February
2005
|
1,894,808 | 1,894,808 | - | 2.5 | - | |||||||||||||||||||||||
May
2005
|
47,500 | 47,500 | 1.62 | 47,500 |
May
2010
|
|||||||||||||||||||||||
June
2005
|
30,000 | 30,000 | 0.75 | 30,000 |
June
2010
|
|||||||||||||||||||||||
August
2005
|
70,000 | 70,000 | - | 0.15 | - | - | ||||||||||||||||||||||
September
2005
|
3,000 | 3,000 | - | 0.15 | - | - | ||||||||||||||||||||||
September
2005
|
36,000 | 36,000 | 0.75 | 36,000 |
September
2010
|
|||||||||||||||||||||||
September-December
2005
|
500,000 | 500,000 | - | 1 | - | - | ||||||||||||||||||||||
December
2005
|
20,000 | 20,000 | - | 0.15 | - | - | ||||||||||||||||||||||
December
2005
|
457,163 | 457,163 | 0.15 | 457,163 |
July
2010
|
|||||||||||||||||||||||
February
2006
|
230,000 | 230,000 | 0.65 | 230,000 |
February
2016
|
|||||||||||||||||||||||
February
2006
|
40,000 | 40,000 | 1.5 | 40,000 |
February
2011
|
|||||||||||||||||||||||
February
2006
|
8,000 | 8,000 | 0.15 | 8,000 |
February
2011
|
|||||||||||||||||||||||
February
2006
|
189,000 | 97,696 | 91,304 | - | 0. 5 | - | - | |||||||||||||||||||||
May
2006
|
50,000 | 50,000 | 0.0005 | 50,000 |
May
2016
|
|||||||||||||||||||||||
May
-December 2006
|
48,000 | 48,000 | 0.35 | 48,000 |
May
- December 2011
|
|||||||||||||||||||||||
May
-December 2006
|
48,000 | 48,000 | 0.75 | 48,000 |
May
- December 2011
|
|||||||||||||||||||||||
May
2006
|
200,000 | 200,000 | 1 | 200,000 |
May
2011
|
|||||||||||||||||||||||
June
2006
|
24,000 | 24,000 | 0.15 | 24,000 |
June
2011
|
|||||||||||||||||||||||
May
2006
|
19,355 | 19,355 | 0.15 | 19,355 |
May
2011
|
|||||||||||||||||||||||
October
2006
|
630,000 | 630,000 | - | 0.3 | - | - | ||||||||||||||||||||||
December
2006
|
200,000 | 200,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March
2007
|
200,000 | 200,000 | 0.47 | 200,000 |
March
2012
|
|||||||||||||||||||||||
March
2007
|
500,000 | 500,000 | 0.47 | 416,667 |
March
2017
|
|||||||||||||||||||||||
March
2007
|
50,000 | 50,000 | 0.15 | 50,000 |
March
2010
|
|||||||||||||||||||||||
March
2007
|
15,000 | 15,000 | 0.15 | 15,000 |
February
2012
|
|||||||||||||||||||||||
February
2007
|
50,000 | 50,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March
2007
|
225,000 | 225,000 | - | 0.45 | - | - | ||||||||||||||||||||||
March
2007
|
50,000 | 50,000 | 0.45 | 50,000 |
March
2010
|
|||||||||||||||||||||||
April
2007
|
33,300 | 25,000 | 8,300 | 0.45 | 8,300 |
April
2010
|
||||||||||||||||||||||
May
2007
|
250,000 | 250,000 | - | 0.45 | - | - | ||||||||||||||||||||||
July
2007
|
500,000 | 500,000 | 0.39 | 361,111 |
July
2017
|
|||||||||||||||||||||||
September
2007
|
500,000 | 500,000 | 0.15 | 500,000 |
August
2017
|
|||||||||||||||||||||||
August
2007
|
7,562,500 | 7,562,500 | 0.2 | 7,562,500 |
November
2013
|
|||||||||||||||||||||||
July
2007
|
30,000 | 30,000 | - | 0.45 | - | - | ||||||||||||||||||||||
July
2007
|
100,000 | 100,000 | 0.45 | 100,000 |
July
2010
|
|||||||||||||||||||||||
October
2007
|
200,000 | 200,000 | 0.15 | 200,000 |
August
- October 2017
|
|||||||||||||||||||||||
November
2007
|
2,520,833 | 2,520,833 | 0.20 | 2,520,833 |
November
2013
|
|||||||||||||||||||||||
November
2007
|
2,016,667 | 2,016,667 | 0.29 | 2,016,667 |
November
2013
|
|||||||||||||||||||||||
April
2008
|
4,537,500 | 4,537,500 | 0.29 | 4,537,500 |
November
2013
|
|||||||||||||||||||||||
August
2008
|
3,529,166 | 3,529,166 | 0.29 | 3,529,166 |
November
2013
|
|||||||||||||||||||||||
August
2008
|
1,083,333 | 1,083,333 | 0.29 | 1,008,333 |
November
2013
|
|||||||||||||||||||||||
November
2008
|
100,000 | 100,000 | 0.15 | 100,000 |
September
2018
|
|||||||||||||||||||||||
April
2009
|
200,000 | 200,000 | 0.1 | - |
April
2019
|
|||||||||||||||||||||||
A
|
||||||||||||||||||||||||||||
43,523,970 | 5,692,621 | 3,376,112 | 34,455,237 | 34,033,016 |
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
a)
|
Warrants:
(Cont.)
|
|
b)
|
Shares:
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
|
b)
|
Shares:
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
b)
|
Shares:
(Cont.)
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
|
b)
|
Shares:
(Cont.)
|
|
B.
|
Issuance
of shares, warrants and options:
(Cont.)
|
|
3.
|
Shares
and warrants to service providers:
(Cont.)
|
|
b)
|
Shares:
(Cont.)
|
Nine
months ended
September
30,
|
Year ended
December
31,
|
|||||||||||||||
2009
|
2008
|
|||||||||||||||
Amount
of shares
|
Weighted
average issue price
|
Amount
of shares
|
Weighted
average issue price
|
|||||||||||||
$
|
$
|
|||||||||||||||
Outstanding
at beginning of period
|
2,941,224 | 0.85 | 2,851,224 | 0.86 | ||||||||||||
Issued
|
2,764,284 | 0.075 | 90,000 | 0.40 | ||||||||||||
Outstanding
at end of period
|
5,705,508 | 0.25 | 2,941,224 | 0.85 |
Three
months
Ended
September
30,
|
Nine
months
ended
September
30,
|
Period
from September 22, 2000 (inception date) through
September
30,
|
||||||||||||||||||
2009
|
2008
|
2009
|
2008
|
2009
|
||||||||||||||||
Unaudited
|
Unaudited
|
Unaudited
|
||||||||||||||||||
Research
and development
|
42 | 76 | 223 | 121 | 16,848 | |||||||||||||||
General
and administrative
|
138 | 192 | 340 | 397 | 7,923 | |||||||||||||||
Financial
expenses, net
|
- | 36 | - | 36 | 56 | |||||||||||||||
Total
stock – based compensation expense
|
180 | 304 | 563 | 554 | 24,827 |
a.
|
On
October 28, 2009 the Company issued to shareholder 9,916,667 shares of
Common Stock (See note 7(B)(1)(f)).
|
b.
|
On
October 2, 2009 the Company issued 1,250,000 Shares of Common Stock to
service provider for one year of public relations work. If the Company
decides to terminate the agreement with the service provider prior to the
six month anniversary of the date of such agreement, then 625,000 shares
of Common Stock will be canceled and returned to the
Company.
|
·
|
Developing
the cell differentiation process according to Food and Drug Administration
(“FDA”) and the European agency for evaluation of medical product (“EMEA”)
guidelines;
|
·
|
Demonstrating
safety and efficacy first in animals and then in human patients;
and
|
·
|
Setting
up centralized facilities to provide the therapeutic products and services
for transplantation in
patients.
|
·
|
our
ability to obtain funding from third parties, including any future
collaborative partners;
|
·
|
the
scope, rate of progress and cost of our pre-clinical and clinical trials
and other research and development
programs;
|
·
|
the
time and costs required to gain regulatory
approvals;
|
·
|
the
terms and timing of any collaborative, licensing and other arrangements
that we may establish;
|
·
|
the
costs of filing, prosecuting, defending and enforcing patents, patent
applications, patent claims, trademarks and other intellectual property
rights;
|
·
|
the
effect of competition and market developments;
and
|
·
|
future
pre-clinical and clinical trial
results.
|
·
|
The
Company did not maintain effective controls over certain aspects of the
financial reporting process because we lacked a sufficient complement of
personnel with a level of accounting expertise and an adequate supervisory
review structure that is commensurate with the Company’s financial
reporting requirements. Specifically, our Chief Financial Officer handles
all accounting issues of the Company alone as the Company terminated the
Company’s accountant as part of the downsizing of the Company’s employee
base.
|
|
·
|
Due
to the decrease in the Company's activities and limited cash resources,
the Company manually inputs all purchase and order activities and
confirmation process instead of via an ERP
system.
|
BRAINSTORM
CELL THERAPEUTICS INC.
|
|||
November
16, 2009
|
By:
|
/s/
Rami Efrati
|
|
Name:
Rami Efrati
|
|||
Title:
Chief Executive Officer (Principal Executive Officer)
|
November
16, 2009
|
By:
|
/s/
David Stolick
|
|
Name:
David Stolick
|
|||
Title:
Chief Financial Officer (Principal Financial and Accounting
Officer)
|
Exhibit
Number
|
Description
|
|
10.1
|
Amendment
to Subscription Agreement, dated as of July 31, 2009, by and between ACCBT
Corp. and Brainstorm Cell Therapeutics Inc. is incorporated herein by
reference to Exhibit 10.1 of the Company's Current Report on Form 8-K
dated August 18, 2009 (File No. 333-61610).
|
|
31.1
|
Certification
of the Principal Executive Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
31.2
|
Certification
of the Principal Financial Officer pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Certification
of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|
32.2
|
Certification
of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|